Recent developments include corporate governance changes and regulatory progress for product candidates.

• MIRA Pharmaceuticals appointed a new board member and chairman, indicating changes in corporate governance and leadership [N1].
• The company submitted an Investigational New Drug (IND) application to the FDA for Ketamir-2, marking a key regulatory milestone in its clinical development program [N2].

MIRA Pharmaceuticals has advanced its clinical development pipeline with key milestones such as the submission of an IND application for Ketamir-2 to the FDA. The company maintains a strong liquidity position relative to its current liabilities as of the end of 2025, supported by cash, short-term investments, and recent capital raises through an ATM offering. The appointment of new board leadership may strengthen governance and strategic oversight. If clinical development and regulatory approvals progress successfully, MIRA could establish a foundation for future commercialization efforts.

MIRA Pharmaceuticals faces substantial risks including its early development stage with no revenues, recurring operating losses, and substantial doubt about its ability to continue as a going concern without additional funding. The company depends heavily on successful clinical development and regulatory approval of novel drug candidates, which are inherently uncertain and costly. Potential conflicts of interest and part-time executive leadership may affect operational effectiveness. The lack of patent protection for MIRA-55 and reliance on third-party suppliers and manufacturers add to execution risks. Failure to secure sufficient capital could lead to delays or curtailment of development programs.

MIRA Pharmaceuticals’ moat is limited given its early-stage status, lack of marketed products, and absence of patent protection for key candidates such as MIRA-55. Its competitive position depends on successful clinical development and regulatory approval of its product candidates. The company’s licensing relationship with MIRALOGX provides access to patent-pending rights for Ketamir-2, but also introduces potential conflicts of interest. The reliance on third-party manufacturers and suppliers, as well as the absence of a sales and marketing infrastructure, further constrain its competitive advantages at this stage.

• Going Concern and Liquidity Risk: The company has substantial doubt about its ability to continue as a going concern beyond 12 months without securing additional funding. Failure to obtain capital on acceptable terms may require reducing or eliminating development efforts [S1].
• Early Stage and No Revenues: MIRA is an early development-stage company with no revenues and a limited operating history, making it difficult to evaluate its operations and increasing the risk of failure [S1].
• Regulatory and Clinical Development Risk: The success of MIRA depends on the successful clinical development, FDA regulatory approval, and commercialization of Ketamir-2 and MIRA-55, which are novel drug candidates with uncertain outcomes [S1].
• Intellectual Property Risk: MIRA has no issued patents for MIRA-55, which may adversely impact its competitive position and market potential [S1].
• Reliance on Third Parties: The company depends on third-party suppliers, manufacturers, and contract research organizations for clinical trials and production, exposing it to risks of supply interruptions, regulatory non-compliance, and quality control issues [S1].
• Conflicts of Interest: Potential conflicts of interest exist due to relationships with MIRALOGX, which licenses patent rights to Ketamir-2 and is owned by a major stockholder, and due to part-time employment of key executives [S1].
• Market and Economic Risks: Unfavorable global economic and geopolitical conditions, as well as legislative or regulatory reforms in healthcare, may adversely affect the company’s business and financial condition [S1].

• MIRA Pharmaceuticals, Inc. is an early development-stage pharmaceutical company focused on developing pre-clinical and clinical drug candidates, principally Ketamir-2 and MIRA-55 [S1].
• The company has no revenues and has incurred recurring losses, with a net loss of $10,442,485 for the fiscal year ended December 31, 2025 [S1].
• As of December 31, 2025, MIRA had cash and cash equivalents of $6,346,921 and short-term investments of $4,683,099, totaling current assets of $11,058,166 against current liabilities of $702,068, resulting in a current ratio of 15.75 and a cash ratio of 15.71 [S1].
• The company has substantial doubt about its ability to continue as a going concern beyond the 12 months following the issuance of its 2025 financial statements, due to lack of revenues and recurring losses [S1].
• MIRA plans to secure additional capital through public or private equity offerings and strategic transactions, but none are committed at this time [S1].
• The company has filed a shelf registration statement and entered into an At The Market Offering Agreement with Rodman & Renshaw LLC, with a maximum amount eligible to be sold of $75 million; net proceeds of $6.7 million were received in 2025 [S1].
• MIRA depends on third-party suppliers and manufacturers for materials and production of its product candidates, with risks related to supply interruptions and regulatory compliance [S1].
• The company relies on third parties to conduct clinical trials and manage data, with limited control over their activities [S1].
• MIRA has no drug products on the market and all drug development projects are in pre-clinical or early clinical stages [S1].
• The company’s future viability depends on successful development, regulatory approval, and commercialization of Ketamir-2 and MIRA-55, which require significant capital and time [S1].
• MIRA has no issued patents for MIRA-55, which may affect its competitive position [S1].
• Conflicts of interest may arise due to relationships with MIRALOGX, which licenses patent rights to Ketamir-2 and is owned by the Bay Shore Trust, also a major stockholder of MIRA [S1].
• Certain executive officers, including the CEO and CFO, are not employed full-time by the company, which may affect availability and create potential conflicts of interest [S1].
• Recent corporate developments include the appointment of a new board member and chairman [N1].
• MIRA submitted an Investigational New Drug (IND) application to the FDA for Ketamir-2 [N2].